Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionitrile SCHEMBL5577903 | 0.96 | DTYMK (0.70) | DTYMKMEN1POLBKMT2ATSHR | |
| SCHEMBL29353295 | 0.87 | DTYMK (1.00) | DTYMKMEN1POLBKMT2ATSHR | |
| SCHEMBL143541 | 0.87 | DTYMK (1.00) | DTYMKMEN1POLBKMT2ATSHR | |
| SCHEMBL26775 | 0.87 | DTYMK (1.00) | DTYMKMEN1POLBKMT2ATSHR | |
| SCHEMBL29388000 | 0.85 | DTYMK (0.97) | DTYMKMEN1POLBKMT2ATSHR | |
| SCHEMBL8577281 | 0.85 | DTYMK (0.97) | DTYMKMEN1POLBKMT2ATSHR | |
| SCHEMBL19885315 | 0.83 | DTYMK (0.85) | DTYMKMEN1POLBKMT2ATSHR | |
| SCHEMBL16489112 | 0.82 | DTYMK (0.82) | DTYMKMEN1POLBKMT2ATSHR | |
| SCHEMBL13715527 | 0.81 | DTYMK (0.82) | DTYMKMEN1POLBKMT2ATSHR | |
| SCHEMBL381244 | 0.80 | DTYMK (0.69) | DTYMKMEN1POLBKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191281-A1 | Compound containing a labile disulfide bond | ROCHE MADISON INC. | 2007-08-16 | — | — | US | disclosed |
| US-7087770-B2 | Compound containing a labile disulfide bond | MIRUS BIO CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1667728-A1 | INTRAVASCULAR DELIVERY OF NON-VIRAL NUCLEIC ACID | Mirus Bio Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| US-6936729-B2 | Compound containing a labile disulfide bond | MIRUS BIO CORPORATION (US) | 2005-08-30 | — | — | US | disclosed |
| US-6897068-B2 | Polynucleotide complex delivery | MIRUS BIO CORPORATION (US) | 2005-05-24 | — | — | US | disclosed |
| WO-2005009476-A1 | INTRAVASCULAR DELIVERY OF NON-VIRAL NUCLEIC ACID | MIRUS CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020518-A9 | Compound containing a labile disulfide bond | ROCHE MADISON INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040106567-A1 | Intravascular delivery of non-viral nucleic acid | HAGSTROM JAMES E (US) | 2004-06-03 | — | — | US | disclosed |
| US-20040072785-A1 | Intravascular delivery of non-viral nucleic acid | WOLFF JON A (US) | 2004-04-15 | — | — | US | disclosed |
| US-20030216347-A1 | Intravascular delivery of non-viral nucleic acid | MONAHAN SEAN D (US) | 2003-11-20 | — | — | US | disclosed |
| US-20030166280-A1 | Polynucleotide complex delivery | Arrowhead Madison Inc. | 2003-09-04 | — | — | US | disclosed |
| US-20010044417-A1 | Compound containing a labile disulfide bond | WOLFF JON A (US) | 2001-11-22 | — | — | US | disclosed |
| US-20010036926-A1 | Compound containing a labile disulfide bond | ROCHE MADISON INC. | 2001-11-01 | — | — | US | disclosed |
| US-20010004636-A1 | INTRAVASCULAR DELIVERY OF NON-VIRAL NUCLEIC ACID | Arrowhead Madison Inc. | 2001-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166280-A1 | Polynucleotide complex delivery | POLI, POLN, POLRMT | DTYMK 207/4885MEN1 3177/4885POLB 12/4885 |
| US-20070191281-A1 | Compound containing a labile disulfide bond | P4HB, HSF1, ATF4 | DTYMK 1423/4885MEN1 4467/4885POLB 4511/4885 |
| US-20010036926-A1 | Compound containing a labile disulfide bond | GPX4, GPX1, GSTK1 | DTYMK 475/4885MEN1 3930/4885POLB 3927/4885 |
| US-20010004636-A1 | INTRAVASCULAR DELIVERY OF NON-VIRAL NUCLEIC ACID | HNRNPH1, HNRNPA1, HNRNPH3 | DTYMK 509/4885MEN1 3095/4885POLB 213/4885 |
| US-20050020518-A9 | Compound containing a labile disulfide bond | P4HB, HSF1, ATF4 | DTYMK 1423/4885MEN1 4467/4885POLB 4511/4885 |
| US-20010044417-A1 | Compound containing a labile disulfide bond | P4HB, HSF1, ATF4 | DTYMK 1423/4885MEN1 4467/4885POLB 4511/4885 |
| US-20030216347-A1 | Intravascular delivery of non-viral nucleic acid | HNRNPH1, HNRNPA1, HNRNPH3 | DTYMK 509/4885MEN1 3095/4885POLB 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.